This pharmaceutical stock exhibits strong fundamentals and is also displaying promising technical indicators. Lower time frames show signs of a potential reversal, and the most recent monthly candle has rejected lower levels, aiming for key Gann levels at 4263. A safe entry point lies above this level, but for those with a higher risk tolerance, entry may be considered now with a stop-loss at 3385 levels.